Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBEC-guided versus MIC-guided antibiotic therapy for periprosthetic joint infection
2024-518350-17-00Phase 4Authorised
- Sponsor
- Region Västra Götaland
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of linezolid, fusidic acid, rifampicin, levofloxacin, trimethoprim + sulfamethoxazole and 3 more in Periprosthetic Hip Infection (PHI) and periprosthetic joint infection (PJI) (2 arms), sponsored by Region Västra Götaland. Primary endpoint: Proportion of non–first-line antimicrobial regimens after susceptibility guidance. Planned start Oct 2024; status: authorised.
02
Drugs
linezolidfusidic acidrifampicinlevofloxacintrimethoprim + sulfamethoxazole
03
Conditions
Periprosthetic Hip Infection (PHI)periprosthetic joint infection (PJI)
Beyond the preview
Go deeper on 2024-518350-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518350-17-00.